Anti-epidermal growth factor receptor strategies for advanced breast cancer

Cancer Investigation

Volumn 26, Issue 8, 2008, Pages 757-768

  Campos, Susana M ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FULVESTRANT; GEFITINIB; LAPATINIB; TRASTUZUMAB;

ACNE; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; GENES, ERBB-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TREATMENT OUTCOME;

EID: 53949104487     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801971040     Document Type: Review

References (129)

1. Mendelsohn, J.; Baselga, J. The EFG receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550-6565.
2. El-Rayes, B.; LoRusso, T. Targeting the epidermal growth factor receptor. Br J Cancer 2004, 91, 418-424.
3. Nahta, R.; Esteva, F.J. Her 2 targeted therapy: lessons learned and future directions. Clin Cancer Res 2003, 9, 5078-5084.
4. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
5. Simon, M.A. Receptor tyrosine kinases specific outcomes from general signals. Cell 2000, 103, 13-15.
6. Daly, R.J. Take your partners please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 1999, 16, 255-263.
7. Riese, D.J II.; Stern, D.F. Specificity within the EGF/ErbB receptor family. Signaling network. Bioessays 1998, 20, 41-48.
8. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; et al. The ErbB signaling network receptor heterodimerization in development and cancer. EMBO J 2000, 19, 3154-3167.
9. Salomon, D.S.; Brandt, R.; Ciardiello, F.; et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19, 183-232.
10. Sporn, M.B.; Roberts, A.B. Autocrine secretion-10 years later. Ann Intern Med 1992, 117, 408-414.
11. Tzahar, E.; Pinkas-Kramarski, R.; Moyer, J.D.; et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 1997, 16, 4938-4950.
12. Cohen, S.; Carpenter, G. Human, epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci USA 1975, 72, 1317-1321.
13. Derynck, R. Transforming growth factor alpha. Cell 1988, 54, 593-595.
14. Schreiber, A.B.; Winkler, M.E.; Derynck, R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986, 232, 1250-1253.
15. Ennis, B.W.; Lippman, M.E.; Dickson, R.B. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991, 9, 553-562.
16. Klijn, J.G.; Berns, P.M.; Schmitz, P.I.; et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients. Endocr Rev 1992, 13, 3-17.
17. Bucci, B.; D'Agnano, I.; Botti, C.; et al. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Res 1997, 17, 769-774.
18. Klijn, J.G.; Look, M.P.; Portengan, H.; et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10-year follow-up study. Breast Cancer Res Treat 1994, 29, 73-83.
19. Ullrich, A.; Coussens, L.; Hayflick, J.S.; et al. Human epidermal growth factor receptor CDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
20. Petrides, P.E.; Bock, S.; Bovens, J.; et al. Modulation of proepidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor gene expression in human renal carcinomas. Cancer Res 1990, 50, 3934-3939.
21. Collins, V.P. Gene amplification in human gliomas. Glia 1995, 15, 289-296.
22. Reissman, P.T.; Koga, H.; Figlin, R.A.; et al. Amplification and overexpression of the cyclin Dl and epidermal growth factor receptor genes in non small cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999, 125, 61-70.
23. Stumm, G.; Eberwein, S.; Rostock-Wolf, S.; et al. Concomitant expression of the EGFR and erbB2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996, 69, 17-22.
24. Kazan, R.B.; Norton, L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998, 273, 9078-9084.
25. Shibata, T.; Kawano, T.; Nagayasu, H.; et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 1996, 17, 168-175.
26. de Jong, J.S.; van Diest, P.J.; van der Valk, P.; Baak.; J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J. Path 1998, 184, 53-57.
27. Morishige, K.; Kurachi, H.; Amemiya, K.; et al. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991, 51, 5322-5328.
28. Gibson, S.; Tu, S.; Oyer, R.; et al. Epidermal growth factor protects epithelial cells against Fas induced apoptosis: requirement for Akt activation. J Biol Chem 1999, 274, 17612-17618.
29. Moscatello, D.K.; Holgado-Madruga, M.; Emlet, D.R.; et al. Constitutive activation of phosphatidylinositol 3 kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273, 200-206.
30. Moscatello, D.K.; Holgado-Madruga, M.; Godwin, A.K.; et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55, 5536-5539.
31. Chu, C.T.; Everiss, KD.;Wikstrand, C.J.; et al. Receptor dimerization is not a factor in signal ing activity of a transforming variant epidermal growth factor receptor (EGFR VIII). Biochem J 1997, 324, 855-886.
32. Semba, K.; Kamata, N.; Toyoshima, K.; Yamamoto, T. A verb B related protooncogene, cerbB-2, is distinct from c-erb B/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Nati Acad Sci USA 1985, 82, 6497-6501.
33. Peles, E.; Bacus, S.S.; Koski, R.A.; et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992, 69, 205-216.
34. Atalay, G.; Cardoso, F.; Awada, A.; Piccart, M.J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003, 14, 1346-1363.
35. Slamon, D.J.; Godolphin, W.; Jones, L.A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
36. Ross, J.S. Fletcher, J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predicative factor, and target for therapy. Stem Cells 1998, 16, 413-428.
37. Slamon, D.J.; Clark, G.M.; Wong, S.G.; et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
38. Tzahar, E.; Levkkowitz, G.; Karunagarano, D.; et al. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all neu differentiation factor/heregulin isoforms. J Biol Chem 1994, 269, 25226-25233.
39. Xue, C.; Liang, F.; Mahmood, R.; et al. ErbB-3 dependent motility and intravastion in breast cancer metastasis. Cancer Res 2006, 66, 1418-1426.
40. Elenius, K.; Choi, C.J.; Paul, S.; et al. Characterization of a naturally occurring erbB4 isoform that does not bind or activate phosphatidylinositol 3 kinase. Oncogene 1999, 18, 2607-2615.
41. Barnes, N.L.; Khavari, S.; Boland, G.P.; et al. Absence of HER4 expression predicts recur rence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11, 2163-2168.
42. Yarden, Y.; Sliwkowski M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2, 127-137.
43. Olayioye, M.A.; Graus-Porta, D.; Beerli, R.R.; et al. ErbB-1 and ErbB-2 acquire distinct signal properties dependent upon their dimerization partner. Mol Cell Biol 1998, 18, 5042-5051.
44. Ullrich, A.; Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
45. Hackel, P.O.; Zwick, E.; Prenzel, N, et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11, 184-189.
46. Bartlett, J.M.; Langdon, S.P.; Simpson, B.J.; et al. The prognostic value of epidermal growth factor mRNA expression in primary ovarian cancer. Br J Cancer 1996, 73, 301-306.
47. Grandis, J.R.; Melhem, M.F.; Gooding WE, et al. Levels of TGFalpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90, 824-832.
48. Chow, N.H.; Liu, H.S.; Lee, E.l.; et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997, 17, 1293-1296.
49. Eberhard, D.A.; Huntzicker, A.; Anderson, S, et al. Epidermal growth factor receptor immunochemistry (EGFR IHC): assay selection and amplification to breast cancers [abstr 1791]. Pro Am Soc Clin Oncol 2002, 21, 448a.
50. Chung, G.G.; Zerkowski, M.P.; Ocal IT.; et al. B-Catenin and p53 analysis of a breast carcinoma tissue microarray. Cancer 2004, 100, 2084-2092.
51. Kersting, C.; Tidow, N.; Schmidt, H.; et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of EGFR amplifications despite overexpression in invasive breast carcinoma. Lab Invest 2004, 84, 582-587.
52. Rampaul, R.S.; Finder, S.E.; Paish C.; et al. Quantitative analysis of breast cancer tissue microarray in the assessment of HER-2. Eur J Cancer 2003, 1, 4-35.
53. Kumar, R.R.; Meenakshi, A.; Sivakumar N.; et al. Enzyme immunoassay of human epidermal growth factor receptor. Hum Antibodies 2001, 10, 143-147.
54. Robertson, K.W.; Reeves, J.R.; Lannigan A.K.; et al. Radioimmunohistochemistry of epider mal growth factor in breast cancer. Arch Pathol Lab Med 2001, 126, 177-181.
55. Pawlowski, V.; Revillion, F.; Hebbar M.; et al. Prognostic value of the type 1 growth factor receptors in a large series of human primary breast cancers quantified with a real time RT-PCR assay. Clin Cancer Res 2000, 6, 4217-4225.
56. Rampaul, R.S.; Pinder, S.E.; Nicholson, RI.; et al. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 2005, 12, 271-273.
57. Fox, S.; Smith, K.; Hollyer, J.; et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3039 patients. Breast Cancer Res Treat 1994, 29, 41-49.
58. Rampaul, R.S.; Finder, S.E.; Robertson, JF.; et al. EGFR expression in operable breast cancer: is it of prognostic significance? Clin Cancer Res 1997, 3, 1643-1651.
59. Slichenmyer, W.J.; Fry, D.W. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin Oncol 2001, 28 (suppl 16) 67-79.
60. Wakeling, A.E.; Guy, S.P.; Woodburn JR.; et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research 2002, 62, 5749-5754.
61. Anderson, N.G.; Ahmad, T.; Chan, K.; et al. ZD 1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potentially inhibits the growth of EGFR positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001, 94, 774-782.
62. Moulder, S.L.; Yakes, F.M.; Muthuswamy, S.K.; et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits Her2/neu (erbB2)-over expressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61, 8887-8895.
63. Moasser, M.M.; Basso, A.; Averbach, S.D.; et al. The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER 2 driven signaling and suppresses the growth of HER 2 over expressing tumor cells. Cancer Res 2001, 61, 7184-7188.
64. Baselga, J.; Rischin, D.; Ranson, M.; et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20, 4292-4302.
65. Herbst, R.S.; Maddox, A.M.; Rothenberg, M.L.; et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002, 20, 3815-3825.
66. Nakagawa, K.; Tamura, T.; Negoro, S.; et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa," ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003, 14, 922-930.
67. Ranson, M.; Hammond, L.A.; Ferry, D.; et al. ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20, 2240-2250.
68. Albain, K.; Elledge, R.; Gradishar, W.; et al. Open label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer [abstr 20]. Breast Cancer Res Treat 2002, 76 (S1) S33.
69. Von Minckwitz, G.; Jonat, W.; Beckman, M.; et al. A multicenter phase II trial to evaluate Gefitinib ('Iressa', ZD1839) (500 mg/day) in patients with metastatic breast cancer after previous chemotherapy. Eur J Cancer 2003, l (suppl 1) S133.
70. Baselga, J.; Albanell, J.; Ruiz, A.; et al. Phase II and tumor pharmacodynamic study of Gefitinib (ZD 1839) in patients with advanced breast cancer. J Clin Oncol 2006, 23, 5323-5333.
71. Robertson, JFR.; Gutteridge, E.; Cheung, K.L.; et al. Gefitinib (ZD 1839) is active in acquire tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study [abstr 23]. Proc Am Soc Clin Oncol 2003, 22, 7.
72. Levitt, M.L.; Koty, P.P. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 1999, 17, 213-226.
73. Huang, S.M.; Harari, P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999, 17, 259-269.
74. Karp, P.P.; Silberman, S.L.; Sudan, R.; et al. Phase I dose escalation study of anti-epidermal growth factor (EGFR) tyrosine kinase inhibitor CP-358, 774 in patients with advanced solid tumors [abstr 1499]. Proc Am Soc Clin Oncol 1999, 18, 388a.
75. Hidalgo, M.; Siu, L.L.; Nemunaitis, J.; et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19, 3267-3279.
76. Rowinsky, E.K.; Hammond, L.; Siu, L.; et al. Dose-schedule-finding pharmacokinetic, biological and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor [abstr 5]. Proc Am Soc Clin Oncol 2001, 20, 2a.
77. Hammond, L.A.; Denis, L.J.; Salman, U.A.; et al. 18FDG-PET evaluation of patients treated with the epidermal growth factor (EGFR) tyrosine kinase inhibitor, CP-358, 774 [abstr 385]. Clin Cancer Res 2000, 6 (5), 4543s.
78. Winer, E.; Cobleigh, M.; Dickler, M.; et al. Phase II multicenter study to evaluate the effi cacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer [abstr 445]. Breast Cancer Res Treat 2002, 76 (suppl 1), S115.
79. Nanney, L.B.; Stoscheck, C.M.; King, L.E. Jr.; et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990, 94, 742-748.
80. Jost, M.; Kari, C.; Rodeck, U. The EGF receptor: an essential regulator of multiple epider mal functions. Eur J Dermatol 2000, 10, 505-510.
81. Tan, A.R.; Yang, X.; Hewitt, S.M. Evaluation of biological endpoints and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004, 22, 3080-3090.
82. Allen, L.F.; Lenehan, P.F.; Eiseman, I.A.; et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002, 29, 11-21.
83. Fry, D.W.; Bridges, A.J.; Denny, W.A.; et al. Specific, irreversible inactivation of the epider mal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998, 95, 12022-12027.
84. Gieseg, M.A.; de Bock, C.; Ferguson, L.R.; et al. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations for cisplatin and the new irre versible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001, 12, 681-682.
85. Fry, D.W. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 2000, 15, 3-16.
86. Shin, D.M.; Nemunaitis, J.; Zinner, R.G.; et al. A Phase 1 clinical and biomarker study of CI-1033, a novel pan erbB tyrosine kinase inhibitor in patients with solid tumors [abstr 324]. Proc Am Soc Oncol 2001, 20, 82a.
87. Nemunaitis, J.; Eiseman, I.; Cunningham, C.; et al. Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005, 11 (10), 3846-3853.
88. Rusnak, D.W.; Lackey, K.; Affleck, K.; et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1, 85-94.
89. Xia, W.; Mullin, R.J.; Keith, B.R.; et al. Anti-tumor activity of GW572016: a dual kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erkl/2 and AKT pathways. Oncogene 2002, 21, 6255-6263.
90. Burris, H.A. III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004, 9(suppl 3), 10-15.
91. Versola, M.; Burris, H.; Jones, S.; et al. Clinical activity of GW572016 in EGF 10003 in patients with solid tumors. J Clin Oncol 2004, 22, 3047.
92. Burris, H.A.; Hurwitz, H.I.; Dees, E.C.; et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, (23), 5305-5313.
93. Blackwell, K.; Burstein, H.; Pegram, M.; et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refrac tory metastatic breast cancer. Proc Am Soc Oncol 2005, 23, 3004.
94. Burstein, H.; Storniolo, A.M.; Franco, S.; et al. A phase II trial, open label,multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens [abstr 1040]. Ann Oncol 2004, 15 (suppl 3), iii27.
95. Gomez, H.; Chavez, M.; Doval, D.; et al. A Phase II, a randomized trial using the small molecule tyrosine inhibitor lapatinib as a first line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005, 23, 3046.
96. Katz, A.; Zalewski, P. Quality-of-life benefits and evidence of antitumor activity for patients with brain metastases treated with gefitinib. Br J Cancer 2003, 89 (suppl 2), S15-S18.
97. Lin, N.; Carey, L.A.; Liu, M.C.; et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstr 503]. Proc Soc Am Oncol 2006, 24, 3S.
98. Lynch, T.J.; Bell, D.W.; Sordella, R.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness to non- small cell lung cancer to gefitinib. N Engl J Med 2004, 350, 2129-2139.
99. Paez, J.G.; Janne, P.A.; Lee, J.C.; et al. EGFR mutations in lung cancer: correlation with clini cal response to gefitinib therapy. Science 2004, 304, 1497-1500.
100. Lee, J.W.; Soung, Y.H.; Seo, S.H.; et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal and breast carcinomas. Clin Cancer Res 2006, 12, 57-61.
101. Newby, J.C.; Johnston, S.R.; Smith, I.E.; et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997, 3 (9) 1643-1651.
102. Nicholson, R.I.; Gee, J.M. Oestrogen and growth factor crosstalk and endocrine sensitivity and acquired resistance in breast cancer. Br J Cancer 2000, 82, 501-513.
103. Nicholson, R.I.; McClelland, R.A.; Finlay, P.; et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormonal sensi tivity. Eur J Cancer 1993, 29A, 1018-1023.
104. Nicholson, R.I.; McClelland, R.A.; Gee, J.M.; et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994, 29, 117-125.
105. Nicholson, R.I.; Hutcheson, I.R.; Knowlden, J.; et al. Modulation of epidermal growth factor receptor in endocrine resistance, oestrogen receptor positive breast cancer. Endocr Relat Cancer 2001, 8, 175-182.
106. Nicholson, R.I.; Hutcheson, I.R.; Knowlden, J.M.; et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004a, 10, 346S-354S.
107. Knowlden, J.M.; Hutcheson, I.R.; Jones, H.E.; et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory path ways in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144, 1032-1044.
108. Martin, L.A.; Farmer, I.; Johnston, S.R.; et al. Enhanced ER alpha ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestrogen deprivation. J Biol Chem 2003, 278, 30458-30468.
109. McClelland, R.A.; Barrow, D.; Madden, T.A.; et al. Enhanced epidermal growth factor signaling in MCF7 breast cancer cells after long term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142, 2776-2788.
110. Agrawal, A.; Gutteridge, E.; Gee, J.W.; et al. Overview of tyrosine kinase inhibitors in clini cal breast cancer. Endocr Relat Cancer 2005, 12, S135-S144.
111. Jones, H.E.; Goddard, L.; Gee, J.M.; et al. Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD 1839;Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11, 793-811.
112. Gee, M.; Harper, M.E.; Hutcheson, I.R.; et al. The anti-epidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents develop ment of resistance in breast cancer in vitro. Endocrinology 2003, 144, 5105-5117.
113. Cobleigh, M.A.; Vogel, C.L.; Tripathy, D.; et al. Multinational study of the efficacy and safety of humanized anti-HER 2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17, 2639-2648.
114. Vogel, C.L.; Cobleigh, M.A.; Tripathy, D.; et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol 2002, 20, 719-726.
115. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; et al. Use of chemotherapy plus a monoclonal anti body against HER2 metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344, 783-792.
116. Robert, N.; Leyland-Jones, B.; Asmar, L.; et al. Updated results of a randomized phase III trial of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2 overexpressing metastatic breast cancer (MBC): efficacy and safety [abstr 144]. Ann Oncol 2004, 15(suppl 3) 39.
117. Burstein, H.J.; Harris, L.N.; Marcom, P.K.; et al. Trastuzumab and vinorelbine as first line therapy for HER 2-overexpressing breast cancer; multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveil lance algorithm. J Clin Oncol 2003, 21, 2889-2895.
118. Come, S.E.; Buzdar, A.U.; Arteaga, C.L.; et al. Proceedings of the third international confer ence on recent advances and future directions in endocrine manipulation of breast cancer: conference summary statement. Clin Can Res 2004, 10, 327S-330S.
119. Bharwani, L.; Schiff, R.; Mohsin, S.K.; et al. Inhibiting the EGFR/HER2 pathway with gefi tinib and/or trastuzumab restores tamoxifen sensitivity in HER 2 overexpressing tumors. Breast Cancer Res Treat 2003, 82, S13-14.
120. Normanno, N.; Campiglio, M.; DeLuca, A.; et al. The cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002, 13, 65-72.
121. Moulder, S.L.; Arteaga, C.L. A Phase I/II trial of trastuzumab and gefitinib in patient with metastatic breast cancer that overexpresses HER2/neu (erbB-2). Clin Breast Cancer 2003, 4, 142-145.
122. Arpino, G.;Weiss, H.;Wakeling, A.E.; et al. Complete disappearance of ER+/HER2 + breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzu- mab to block HER2 cross talk with ER and restore tamoxifen inhibition [abstr 23]. Breast Cancer Res Treat 2004, 88, S15.
123. Britten, C.D.; Pegram, M.; Rosen, P.; et al. Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic Her2 +breast cancer [abstr 3045]. Proc Am Soc Clin Oncol 2004, 22, 206.
124. Finn, R.S.; Wilson, C.A.; Sanders, J.; et al. Targeting the epidermal growth factor receptor (EGFR) and Her-2 with OSI-774 and trastuzumab, respectively, in HER-2 overexpressing human breast cancer cell lines results in a therapeutic advantage in vitro [abstr 940]. Proc Am Soc Clin Oncol 2003, 22, 235.
125. Jones, S.F.; Burris, H.A.; Yardley, D.A.; et al. Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. Breast Cancer Res Treat 2004, 88 (suppl 1) S64.
126. Schwartz, G.; Chu QS-C.; Hammond, L.a.; et al. Phase I clinical, biology, and pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors [abstr 3070]. Proc Am Soc Oncol 2004, 23, 212.
127. Chu, Q.; Cianfrocca, M.E.; Murray, N.; et al. A phase I, open label study of the safety, toler- ability and pharmacokinetics of lapatinib (GW 572016) in combination with letrozole in cancer patients [abstr 6044]. Breast Cancer Res Treat 2004, 88 (suppl 1) S235.
128. Storniolo, A.M.; Burris, H.; Pegram, M.; et al. A phase I, open label study of lapatinib (GW 572016) plus trastuzumab; a clinically active regimen [abstr 559]. J Clin Oncol 2005, 23 (suppl) 18s.
129. Geyer, C.E.; Cameron, D.; Lindquist, D.; et al. A Phase II randomized, open-label international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer. Scientific Session ASCO 2006.